Cargando…
Photophobia and migraine outcome during treatment with galcanezumab
BACKGROUND: Calcitonin gene-related peptide (CGRP) plays a pivotal role in migraine physiology, not only regarding migraine pain but also associated symptoms such as photophobia. The aim of the present study was to assess monoclonal antibodies targeting CGRP efficacy not only in terms of headache an...
Autores principales: | Schiano di Cola, Francesca, Ceccardi, Giulia, Bolchini, Marco, Caratozzolo, Salvatore, Liberini, Paolo, Padovani, Alessandro, Rao, Renata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889984/ https://www.ncbi.nlm.nih.gov/pubmed/36742057 http://dx.doi.org/10.3389/fneur.2022.1088036 |
Ejemplares similares
-
Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine
por: di Cola, Francesca Schiano, et al.
Publicado: (2023) -
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
por: Schiano di Cola, Francesca, et al.
Publicado: (2022) -
Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment
por: Schiano di Cola, Francesca, et al.
Publicado: (2019) -
Onabotulinumtoxin-a during COVID-19 pandemic: Long-term efficacy in chronic migraine
por: Locatelli, Martina, et al.
Publicado: (2021) -
CGRP-monoclonal antibodies and SARS-CoV-2 vaccination
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)